Compare Amylx Pharmaceuticals Inc (AMLX) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Kroger Co — how do they compare? Amylx Pharmaceuticals Inc trades at $17.34 (market cap $1.98B), while Kroger Co trades at $60.13 (market cap $37.09B). The key difference: Kroger Co is far larger — about 18.7× Amylx Pharmaceuticals Inc's market cap, and Kroger Co pays a 2.38% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KR | |
|---|---|---|
Market Cap | $1.98B | $37.09B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $75.60 |
52-Week Low | $7.64 | $55.53 |
Enterprise Value | $1.70B | $57.18B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Kroger (KR) trades at $60.54, up 1.14% today, near the analyst consensus price target of $68.63. The stock shows bullish technical signals despite a mixed earnings history, with recent beats in Q3 and Q4 2025 but a miss in Q1 2026. Fundamentals reveal a low P/S ratio of 0.26 and steady dividends, while the recent $1.65 billion acquisition of Giant Eagle aims to expand Midwest presence amid intense grocery competition.
KR offers value with solid cash flow and growth initiatives, but risks include margin pressure from industry competition and integration challenges from acquisitions. Analyst sentiment is positive with 48% buy ratings, supporting a cautious bullish outlook for patient investors focused on long-term retail consolidation benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
